Head-to-head · WeighScore
MedLeanRx vs Zealthy
The verdict
MedLeanRx takes it — 73.9/100 to 46.7/100.
MedLeanRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | MedLeanRx | Zealthy |
|---|---|---|
| WeighScore | 73.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #69 | #496 |
| Semaglutide | $149/mo (starting dose, promotional rate, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $269/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 1 states | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #69 · C
Strengths
- Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
- Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
- Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
- LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
- Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips
Where it loses points
- Texas only — not available in the other 49 states
- Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
- Strict no-refund policy: 'All sales are final' per Terms & Conditions
- Pharmacy partner not publicly named — a transparency gap for a compounding service
- Legal entity name and founding details not published on the site
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.